Risk Stratification for Therapeutic Management and Prognosis

Heart Failure Clinics

Volumn 5, Issue 3, 2009, Pages 437-455

  Coelho Filho, Otavio R ^a   Nallamshetty, Leelakrishna ^a   Kwong, Raymond Y ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CMR imaging; Heart failure; Prognosis; Risk stratification

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOBUTAMINE; GADOLINIUM CHELATE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; STEROID;

AMYLOIDOSIS; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CHAGAS DISEASE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DEFIBRILLATOR; ELECTROCARDIOGRAM; ENDOCARDIAL FIBROELASTOSIS; FABRY DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IONIZING RADIATION; IRON OVERLOAD; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; REVIEW; RISK ASSESSMENT; SARCOIDOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEROID THERAPY;

AMYLOIDOSIS; CARDIOMYOPATHIES; CHAGAS CARDIOMYOPATHY; CORONARY ARTERY DISEASE; ENDOMYOCARDIAL FIBROSIS; FABRY DISEASE; HUMANS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE IMAGING, CINE; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; MYOCARDITIS; PROGNOSIS; RISK ASSESSMENT; SARCOIDOSIS;

EID: 67649202918     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2009.02.010     Document Type: Review

References (81)

1. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 4 (2008) e25-146
2. Allman K.C., Shaw L.J., Hachamovitch R., et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 39 7 (2002) 1151-1158
3. Boden W.E., O'Rourke R.A., Teo K.K., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 15 (2007) 1503-1516
4. Nagel E., Lehmkuhl H.B., Bocksch W., et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation 99 6 (1999) 763-770
5. Hundley W.G., Hamilton C.A., Thomas M.S., et al. Utility of fast cine magnetic resonance imaging and display for the detection of myocardial ischemia in patients not well suited for second harmonic stress echocardiography. [see comment]. Circulation 100 16 (1999) 1697-1702
6. Hundley W.G., Morgan T.M., Neagle C.M., et al. Magnetic resonance imaging determination of cardiac prognosis. Circulation 106 18 (2002) 2328-2333
7. Rerkpattanapipat P., Morgan T.M., Neagle C.M., et al. Assessment of preoperative cardiac risk with magnetic resonance imaging. Am J Cardiol 90 4 (2002) 416-419
8. Jahnke C., Nagel E., Gebker R., et al. Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation 115 13 (2007) 1769-1776
9. Dall'Armellina E., Morgan T.M., Mandapaka S., et al. Prediction of cardiac events in patients with reduced left ventricular ejection fraction with dobutamine cardiovascular magnetic resonance assessment of wall motion score index. J Am Coll Cardiol 52 4 (2008) 279-286
10. Jerosch-Herold M., Swingen C., and Seethamraju R.T. Myocardial blood flow quantification with MRI by model-independent deconvolution. Med Pregl 29 5 (2002) 886-897
11. Jerosch-Herold M., Wilke N., and Stillman A.E. Magnetic resonance quantification of the myocardial perfusion reserve with a Fermi function model for constrained deconvolution. Med Pregl 25 1 (1998) 73-84
12. Muehling O.M., Dickson M.E., Zenovich A., et al. Quantitative magnetic resonance first-pass perfusion analysis: inter- and intraobserver agreement. J Cardiovasc Magn Reson 3 3 (2001) 247-256
13. Al-Saadi N., Nagel E., Gross M., et al. Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance. Circulation 101 12 (2000) 1379-1383
14. Panting J.R., Gatehouse P.D., Yang G.Z., et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 346 25 (2002) 1948-1953
15. Schwitter J., Nanz D., Kneifel S., et al. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation 103 18 (2001) 2230-2235
16. Klem I., Heitner J.F., Shah D.J., et al. Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. J Am Coll Cardiol 47 8 (2006) 1630-1638
17. Panting J.R., Gatehouse P.D., Yang G.Z., et al. Echo-planar magnetic resonance myocardial perfusion imaging: parametric map analysis and comparison with thallium SPECT. J Magn Reson Imaging 13 2 (2001) 192-200
18. Wolff S.D., Schwitter J., Coulden R., et al. Myocardial first-pass perfusion magnetic resonance imaging: a multicenter dose-ranging study. Circulation 110 6 (2004) 732-737
19. Giang T.H., Nanz D., Coulden R., et al. Detection of coronary artery disease by magnetic resonance myocardial perfusion imaging with various contrast medium doses: first European multi-centre experience. Eur Heart J 25 18 (2004) 1657-1665
20. Ingkanisorn W.P., Kwong R.Y., Bohme N.S., et al. Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. J Am Coll Cardiol 47 7 (2006) 1427-1432
21. Kwong R.Y., Schussheim A.E., Rekhraj S., et al. Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. Circulation 107 4 (2003) 531-537
22. Schwitter J., Wacker C.M., van Rossum A.C., et al. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J 29 4 (2008) 480-489
23. Gutberlet M., Noeske R., Schwinge K., et al. Comprehensive cardiac magnetic resonance imaging at 3.0 Tesla: feasibility and implications for clinical applications. Invest Radiol 41 2 (2006) 154-167
24. Araoz P.A., Glockner J.F., McGee K.P., et al. 3 Tesla MR imaging provides improved contrast in first-pass myocardial perfusion imaging over a range of gadolinium doses. J Cardiovasc Magn Reson 7 3 (2005) 559-564
25. Cheng A.S., Pegg T.J., Karamitsos T.D., et al. Cardiovascular magnetic resonance perfusion imaging at 3-tesla for the detection of coronary artery disease: a comparison with 1.5-Tesla. J Am Coll Cardiol 49 25 (2007) 2440-2449
26. Simonetti O., Kim R.J., Fieno D.S.., et al. An improved MRI technique for the visualization of myocardial infarction. Radiology 218 1 (2001) 215-223
27. Kim R.J., Chen E.L., Lima J.A., et al. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation 94 12 (1996) 3318-3326
28. Kim R.J., Fieno D.S., Parrish T.B., et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100 19 (1999) 1992-2002
29. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343 20 (2000) 1445-1453
30. Klein C., Nekolla S.G., Bengel F.M., et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation 105 2 (2002) 162-167
31. Wagner A., Mahrholdt H., Holly T.A., et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 361 9355 (2003) 374-379
32. Bello D., Shah D.J., Farah G.M., et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 108 16 (2003) 1945-1953
33. Orn S., Manhenke C., Anand I.S., et al. Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. Am J Cardiol 99 8 (2007) 1109-1114
34. Yano K., and MacLean C.J. The incidence and prognosis of unrecognized myocardial infarction in the Honolulu, Hawaii, Heart Program. Arch Invest Med 149 7 (1989) 1528-1532
35. Kannel W.B., and Abbott R.D. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med 311 18 (1984) 1144-1147
36. Barbier C.E., Bjerner T., Johansson L., et al. Myocardial scars more frequent than expected: magnetic resonance imaging detects potential risk group. J Am Coll Cardiol 48 4 (2006) 765-771
37. Kannel W.B., Cupples L.A., and Gagnon D.R. Incidence, precursors and prognosis of unrecognized myocardial infarction. Adv Cytopharmacol 37 (1990) 202-214
38. Kwong R.Y., Chan A.K., Brown K.A., et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 113 23 (2006) 2733-2743
39. Kwong R.Y., Sattar H., Wu H., et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 118 10 (2008) 1011-1020
40. Schmidt A., Azevedo C.F., Cheng A., et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation 115 15 (2007) 2006-2014
41. Yan A.T., Shayne A.J., Brown K.A., et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 114 1 (2006) 32-39
42. Wu K.C., Zerhouni E.A., Judd R.M., et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 97 8 (1998) 765-772
43. Hombach V., Grebe O., Merkle N., et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 26 6 (2005) 549-557
44. Aletras A.H., Tilak G.S., Natanzon A., et al. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation 113 15 (2006) 1865-1870
45. Cury R.C., Shash K., Nagurney J.T., et al. Cardiac magnetic resonance with T2-weighted imaging improves detection of patients with acute coronary syndrome in the emergency department. Circulation 118 8 (2008) 837-844
46. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 15 (2000) 1077-1084
47. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 21 (2004) 2151-2158
48. Hsia H.H., and Marchlinski F.E. Characterization of the electroanatomic substrate for monomorphic ventricular tachycardia in patients with nonischemic cardiomyopathy. Pacing Clin Electrophysiol 25 7 (2002) 1114-1127
49. Hsia H.H., and Marchlinski F.E. Electrophysiology studies in patients with dilated cardiomyopathies. Card Electrophysiol Rev 6 4 (2002) 472-481
50. Assomull R.G., Prasad S.K., Lyne J., et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48 10 (2006) 1977-1985
51. Wu K.C., Weiss R.G., Thiemann D.R., et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 51 25 (2008) 2414-2421
52. Nazarian S., Bluemke D.A., Lardo A.C., et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation 112 18 (2005) 2821-2825
53. Rickers C., Wilke N.M., Jerosch-Herold M., et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 112 6 (2005) 855-861
54. Moon J.C., Fisher N.G., McKenna W.J., et al. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 90 6 (2004) 645-649
55. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42 9 (2003) 1687-1713
56. Moon J.C., McKenna W.J., McCrohon J.A., et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41 9 (2003) 1561-1567
57. van Dockum W.G., Beek A.M., ten Cate F.J., et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 111 19 (2005) 2503-2508
58. Mahrholdt H., Goedecke C., Wagner A., et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109 10 (2004) 1250-1258
59. Mahrholdt H., Wagner A., Deluigi C.C., et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114 15 (2006) 1581-1590
60. Tandri H., Saranathan M., Rodriguez E.R., et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol 45 1 (2005) 98-103
61. Keller D.I., Osswald S., Bremerich J., et al. Arrhythmogenic right ventricular cardiomyopathy: diagnostic and prognostic value of the cardiac MRI in relation to arrhythmia-free survival. Int J Cardiovasc Imaging 19 6 (2003) 537-543 [discussion:45-7]
62. Maceira A.M., Joshi J., Prasad S.K., et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111 2 (2005) 186-193
63. Falk R.H., and Skinner M. The systemic amyloidoses: an overview. Adv Intern Med 45 (2000) 107-137
64. Falk R.H., Comenzo R.L., and Skinner M. The systemic amyloidoses. N Engl J Med 337 13 (1997) 898-909
65. Sharma O.P., Maheshwari A., and Thaker K. Myocardial sarcoidosis. Chest 103 1 (1993) 253-258
66. Virmani R., Bures J.C., and Roberts W.C. Cardiac sarcoidosis; a major cause of sudden death in young individuals. Chest 77 3 (1980) 423-428
67. White E.S., and Lynch III J.P. Current and emerging strategies for the management of sarcoidosis. Expert Opin Pharmacother 8 9 (2007) 1293-1311
68. Smedema J.P., Snoep G., van Kroonenburgh M.P., et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45 10 (2005) 1683-1690
69. * cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 18 1 (2003) 33-39
70. Tanner M.A., Galanello R., Dessi C., et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 8 3 (2006) 543-547
71. *) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22 23 (2001) 2171-2179
72. Mavrogeni S.I., Markussis V., Kaklamanis L., et al. A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol 75 3 (2005) 241-247
73. * magnetic resonance in heart failure due to thalassaemia. Br J Haematol 128 1 (2005) 2
74. * cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major. J Magn Reson Imaging 22 2 (2005) 229-233
75. Dodd J.D., Holmvang G., Hoffmann U., et al. Quantification of left ventricular noncompaction and trabecular delayed hyperenhancement with cardiac MRI: correlation with clinical severity. AJR Am J Roentgenol 189 4 (2007) 974-980
76. Moon J.C., Mundy H.R., Lee P.J., et al. Images in cardiovascular medicine. Myocardial fibrosis in glycogen storage disease type III. Circulation 107 7 (2003) e47
77. Weidemann F., Breunig F., Beer M., et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26 12 (2005) 1221-1227
78. Weidemann F., Breunig F., Beer M., et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108 11 (2003) 1299-1301
79. Rochitte C.E., Oliveira P.F., Andrade J.M., et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J Am Coll Cardiol 46 8 (2005) 1553-1558
80. Raman S.V., Mehta R., Walker J., et al. Cardiovascular magnetic resonance in endocardial fibroelastosis. J Cardiovasc Magn Reson 7 2 (2005) 391-393
81. Stranzinger E., Ensing G.J., and Hernandez R.J. MR findings of endocardial fibroelastosis in children. Pediatr Radiol 38 3 (2008) 292-296